Plus Therapeutics

04/23/2026

announces the initiation of manufacturing activities and technology transfer with SpectronRx under a previously executed Master Services Agreement, in support of late-stage clinical manufacturing of Rhenium-186 and .

With serving as a second GMP manufacturing site alongside Radiomedix, and Rhenium-186 isotope supplied through Telix Pharmaceuticals Limited, Plus strengthens the reliability of its multi-partner supply chain infrastructure.

Full press release here: bit.ly/4csC045

04/21/2026

announces that it has received notification from The Nasdaq Stock Market confirming has regained compliance with the minimum bid price requirement set forth in Listing Rule 5550(a)(2).

Read more: bit.ly/4vItbuz

04/17/2026

Despite decades of progress in oncology, patients diagnosed with cancers of the central nervous system continue to face limited treatment options and poor outcomes.

is addressing these challenges by strategically rethinking how cancer therapies are designed, delivered, and evaluated. By combining targeted with innovative drug delivery approaches, aims to expand what is possible for patients with some of the most aggressive and underserved cancers.

Learn more about our unique approach from President and CEO, Dr. Marc Hedrick in this Drug Delivery Leader article:

Plus Therapeutics’ approach combines localized radiotherapy with advanced diagnostics and monitoring to improve outcomes for patients with CNS cancers.

04/15/2026

announces the appointment of Randy H. Goodman, Ph.D., M.H.A., as Vice President, Value Strategy & Health Economics and Outcomes Research.

Dr. Goodman’s health economics and reimbursement expertise brings over two decades of experience in payer strategy, value-based pricing, and health policy to support CNSide Diagnostics' adoption and long-term commercialization strategy for REYOBIQ™.

Full press release here: bit.ly/4vBaXLC

04/13/2026

' President and CEO, Dr. Marc Hedrick, joined BioSpace's Denatured Podcast about why could become the next big leap in biotech.

Check out the full episode here:

In this episode of Denatured, you'll listen to Dr. Marc Hedrick, President and CEO of Plus Therapeutics and Dr. Phil Kantoff, CEO & Co-founder of Convergent Therapeutics. They discuss breakthroughs like alpha-emitting isotopes, supply chain solutions and why radiotherapeutics is biotech's next big.....

04/09/2026

announces the appointment of Eric J. Daniels, M.D., MBA, as Chief Development Officer.

Dr. Daniels is a seasoned biotech executive that brings deep experience across clinical development, regulatory strategy, and corporate operations, strengthening ex*****on capabilities as advances its REYOBIQ™ and CNS-focused pipeline.

Full press release here: bit.ly/4cegL4O

04/08/2026

announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation to REYOBIQ™ (rhenium Re186 obisbemeda) for the treatment of pediatric malignant gliomas.

Notably, the granted orphan designation for malignant glioma more broadly than originally requested, encompassing pediatric ependymoma.

Full press release here: bit.ly/4e4A82E

04/07/2026

announces that the American Medical Association has approved a new, Proprietary Laboratory Analyses Current Procedural Terminology code for CNSide Diagnostics' Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) test.

The dedicated billing code, 0640U, effective July 1, 2026, establishes a unique reimbursement identifier for the CSF TCE test, supporting payer claims processing and facilitating broader clinical adoptions as continues the U.S. commercial launch of its CNS metastases diagnostic platform.

Full press release here: bit.ly/4myP1wB

04/02/2026

announces a new payer coverage agreement with Highmark Blue Cross Blue Shield, effective April 1, 2026, providing reimbursement for CNSide Diagnostics' Cerebrospinal Fluid Tumor Cell Enumeration assay for patients with metastatic central nervous system cancers.

joins a growing list of national and regional payers, including UnitedHealthcare and Humana, that provide coverage for ® .

Full press release here: https://bit.ly/3PLOMBV

04/01/2026

issues a proxy letter to stockholders, including an invitation to attend the 2026 Annual Meeting. This meeting will be held on May 14, 2026, commencing at 9:00 a.m. ET, and will be a completely virtual meeting of stockholders.

Read more: bit.ly/4tiC4ZH

Nasdaq:

03/30/2026

Numbers matter in (LM) care.

The CNSide Diagnostics CSF Assay Platform delivers actionable insights from a single cerebrospinal fluid sample. This provides data that can empower clinicians to confirm or rule out LM, and offers the opportunity to monitor disease progression and treatment response through serial testing.

With studies that show CNSide’s enhanced sensitivity vs. CSF cytology and its ability to inform clinical decisions in over 90% of cases, ® is helping clinicians move from uncertainty to clarity.

Learn more: https://cnside-dx.com/cnside-csf-assay/

03/26/2026

announces the appointment of diagnostics industry veteran Ron Andrews to its Board of Directors.

Mr. Andrews currently is an experienced leader in the Diagnostics and Molecular Diagnostics industry with over 35 years leading various sized organizations from divisions of large global entities such as Abbott Diagnostics, Roche Molecular Diagnostics and LifeTechnologies / Thermo Fisher to public CEO roles in successful start-up organizations like Clarient Inc. (NASDAQ: CLRT) and Oncocyte Inc. (NASDAQ: OCX).

Full press release here: bit.ly/3NuNbjb

CNSide Diagnostics